An announcement from Entrada Therapeutics Inc ( (TRDA) ) is now available.
On February 24, 2025, Entrada Therapeutics announced that the FDA has lifted the clinical hold on ENTR-601-44, granting authorization for a Phase 1b clinical study of the drug aimed at treating Duchenne muscular dystrophy (DMD) in adult patients. This significant regulatory milestone allows Entrada to initiate its ELEVATE-44-102 study in the U.S. and expand its global clinical program, potentially positioning the company as a leader in developing therapies for DMD.
More about Entrada Therapeutics Inc
Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing Endosomal Escape Vehicle (EEV™)-therapeutics for the treatment of various diseases including neuromuscular, ocular, metabolic, and immunological disorders. Their lead programs aim to address Duchenne muscular dystrophy by enabling the efficient intracellular delivery of therapeutics.
YTD Price Performance: -25.32%
Average Trading Volume: 115,543
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $488M
Learn more about TRDA stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com